Michael Boxer

1.8k total citations
43 papers, 1.3k citations indexed

About

Michael Boxer is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Michael Boxer has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 18 papers in Pathology and Forensic Medicine and 18 papers in Hematology. Recurrent topics in Michael Boxer's work include Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Michael Boxer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Michael Boxer collaborates with scholars based in United States, United Kingdom and Canada. Michael Boxer's co-authors include Pramod K. Mistry, Gregory M. Pastores, Angelina C. A. Carvalho, Leonard Ellman, Katherine Kacena, Ruhua Yang, Jeff P. Sharman, Kathryn S. Kolibaba, Gilberto Bultron and Daniel S. Pearson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael Boxer

41 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Boxer United States 16 433 394 341 314 198 43 1.3k
Xiaoxia Pan China 22 167 0.4× 142 0.4× 225 0.7× 232 0.7× 32 0.2× 65 1.3k
A. C. Parker United Kingdom 16 630 1.5× 432 1.1× 168 0.5× 394 1.3× 47 0.2× 57 1.3k
Carlo L. Balduini Italy 30 458 1.1× 1.6k 4.1× 80 0.2× 103 0.3× 94 0.5× 67 2.2k
Manfred Weber Germany 19 222 0.5× 225 0.6× 57 0.2× 82 0.3× 79 0.4× 40 1.2k
Bernardo Garicochea Brazil 19 287 0.7× 358 0.9× 40 0.1× 203 0.6× 32 0.2× 67 1.4k
Bruno Royer France 27 741 1.7× 1.1k 2.8× 263 0.8× 414 1.3× 23 0.1× 84 2.5k
Paula G. Heller Argentina 23 528 1.2× 819 2.1× 52 0.2× 61 0.2× 46 0.2× 53 1.2k
Alvina D. Chu United States 18 422 1.0× 272 0.7× 343 1.0× 437 1.4× 18 0.1× 34 2.2k
Candido E. Rivera United States 19 827 1.9× 858 2.2× 79 0.2× 392 1.2× 18 0.1× 50 1.8k
Sylvia Bellucci France 22 884 2.0× 1.4k 3.6× 42 0.1× 119 0.4× 196 1.0× 80 2.1k

Countries citing papers authored by Michael Boxer

Since Specialization
Citations

This map shows the geographic impact of Michael Boxer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Boxer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Boxer more than expected).

Fields of papers citing papers by Michael Boxer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Boxer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Boxer. The network helps show where Michael Boxer may publish in the future.

Co-authorship network of co-authors of Michael Boxer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Boxer. A scholar is included among the top collaborators of Michael Boxer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Boxer. Michael Boxer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kuter, David J., Kerry A. Rogers, Michael Boxer, et al.. (2022). Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study. American Journal of Hematology. 97(6). 691–699. 26 indexed citations
2.
3.
Boccia, Ralph V., Nichola Cooper, Waleed Ghanima, et al.. (2020). Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia. British Journal of Haematology. 190(6). 933–938. 46 indexed citations
4.
Boxer, Michael, et al.. (2019). Etiologies of Thrombocytopenia in the Community Hospital: The Experience of 1 Hematologist. The American Journal of Medicine. 133(5). e183–e186. 1 indexed citations
5.
Rogers, Kerry A., Michael Boxer, Michael Y. Choi, et al.. (2019). Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. Blood. 134(Supplement_1). 3518–3518. 3 indexed citations
6.
Duliège, Anne‐Marie, Donald M. Arnold, Ralph V. Boccia, et al.. (2018). Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program. Blood. 132(Supplement 1). 736–736. 8 indexed citations
7.
8.
Scherber, Robyn M., Heidi Kosiorek, Amylou C. Dueck, et al.. (2015). Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 122(3). 477–485. 46 indexed citations
9.
Sharman, Jeff P., Leonard M. Klein, Michael Boxer, et al.. (2015). Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL). Blood. 126(23). 1545–1545. 12 indexed citations
10.
Scherber, Robyn M., Amylou C. Dueck, Matthew Clark, et al.. (2014). The Impact of Medical Comorbidities in MPN-Related Fatigue. Blood. 124(21). 1862–1862. 3 indexed citations
11.
Scherber, Robyn M., Amylou C. Dueck, Matthew M. Clark, et al.. (2014). High Prevalence of Mood Disorders in MPNs and Their Possible Role in MPN Related Fatigue. Blood. 124(21). 3173–3173. 5 indexed citations
12.
Boxer, Michael, et al.. (2012). “Best-First” Or “Worst-First”: Which Is The Best Policy?. Transportation Research Board 91st Annual MeetingTransportation Research Board. 2 indexed citations
13.
Boxer, Michael. (2012). Consultation for Thrombocytopenia in Hospitalized Patients. Blood. 120(21). 4659–4659. 1 indexed citations
14.
Taddei, Tamar H., Katherine Kacena, Mei Yang, et al.. (2009). The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. American Journal of Hematology. 84(4). 208–214. 118 indexed citations
15.
Hunter, Zachary R., Michael Boxer, Brad S. Kahl, et al.. (2006). Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02–079. Journal of Clinical Oncology. 24(18_suppl). 7523–7523. 21 indexed citations
16.
Edwards, Jon, et al.. (1985). 0.6 T Magnetic Resonance Imaging of the Orbit. American Journal of Neuroradiology. 6(2). 253–258. 10 indexed citations
17.
Boxer, Michael. (1978). Thromboembolic Risk of Postsplenectomy Thrombocytosis. Archives of Surgery. 113(7). 808–808. 125 indexed citations
18.
Boxer, Michael. (1977). Anemia in Primary Hyperparathyroidism. Archives of Internal Medicine. 137(5). 588–588. 64 indexed citations
19.
Kleiger, Robert E., et al.. (1976). Pulmonary Hypertension in Patients Using Oral Contraceptives. CHEST Journal. 69(2). 143–147. 59 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoxia Pan Breakdown of academic impact, for papers by A. C. Parker Breakdown of academic impact, for papers by Carlo L. Balduini Breakdown of academic impact, for papers by Manfred Weber Breakdown of academic impact, for papers by Bernardo Garicochea Breakdown of academic impact, for papers by Bruno Royer Breakdown of academic impact, for papers by Paula G. Heller Breakdown of academic impact, for papers by Alvina D. Chu Breakdown of academic impact, for papers by Candido E. Rivera Breakdown of academic impact, for papers by Sylvia Bellucci
Rankless by CCL
2026